Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2020-06-11 Earnings Release
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Final Results
Earnings Release Classification · 100% confidence The document explicitly states 'Final Results for the Year Ended 31 March 2020' and provides detailed financial performance metrics (Net assets, NAV total return, portfolio valuations, capital pool figures) and operational progress for the entire fiscal year. This content structure is characteristic of a comprehensive annual financial report. Although it is distributed via RNS (RNS Number: 6006P), the core content is the full annual results, which aligns best with the Annual Report (10-K) definition, even if the official SEC filing might be a separate document. Given the depth of financial review covering the full year, it is classified as the Annual Report content, not just a publication announcement (RPA). FY 2020
2020-06-11 English
Autolus presents additional data on AUTO3 in DLBCL
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated May 29, 2020. It is an announcement from Syncona Limited regarding an update from its portfolio company, Autolus Therapeutics, concerning new clinical data presented at the ASCO20 Virtual Scientific Program. The text explicitly states that the full text of the announcement from Autolus is contained below and provides details for an upcoming conference call/webcast to discuss the data. The presence of the RNS header, the nature of the content (a brief update referencing a more detailed presentation/call), and the explicit mention of the RNS service provider strongly indicate this is a general regulatory announcement rather than a full financial report (like 10-K or IR) or a presentation itself (IP). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate fallback is RNS (Regulatory Filings). The document length (11,262 chars) is substantial, but its structure is that of a news release disseminated via an official channel (RNS) reporting on another company's scientific progress, not the scientific report itself.
2020-05-29 English
First patient dosed in Achilles’ melanoma study
Environmental & Social Information Classification · 99% confidence The document begins with an 'RNS Number' and is dated May 29, 2020. It announces a specific corporate event: a portfolio company (Achilles Therapeutics) dosing the first patient in a clinical study. The text structure, including the 'Enquiries' section and the closing statement referencing 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority', strongly indicates this is a regulatory news service announcement. Since it is a general announcement of a significant corporate development (clinical trial milestone) that doesn't fit perfectly into specific categories like ER, DIV, or CAP, the most appropriate classification is the general regulatory filing category, RNS.
2020-05-29 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is extremely short (2245 characters) and its primary purpose is to announce *when* the company will release its 'final results' (which would be an ER or IR/10-K) and provide details on the associated presentation and Q&A session. The title is 'Notice of Final Results'. This fits the definition of announcing the publication of a report rather than being the report itself. The document is distributed via RNS, which is a general regulatory news service. Therefore, the most appropriate classification is Report Publication Announcement (RPA), as it announces the publication of future results and associated events (presentation/Q&A).
2020-05-20 English
Autolus reports Q1 2020 Financial Results
Earnings Release Classification · 100% confidence The document is an RNS announcement (RNS Number : 2997M) from Syncona Limited, noting that its portfolio company, Autolus Therapeutics Plc, announced its operational and financial results for the first quarter ended March 31, 2020. The text provided is the full content of Autolus' announcement, which details financial results (cash, expenses, net loss per share) and operational/pipeline updates. This structure—a brief announcement referencing the release of detailed financial figures for a specific period (Q1 2020)—is characteristic of an Earnings Release (ER). Although it contains financial details, it is presented as a press release summarizing the results, not the comprehensive statutory report (like a 10-Q or 10-K). Since it is the initial announcement of periodical financial results, ER is the most appropriate classification. It is not a Call Transcript (CT) as it lacks Q&A formatting, nor is it a full Interim Report (IR) as it is presented as a summary press release, not the full statutory filing. Q1 2020
2020-05-07 English
New commitment to SwanBio
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a significant investment commitment ($51.0 million new commitment) in a private company (SwanBio Therapeutics) by Syncona Limited. This type of announcement, concerning financing, investment, or material corporate updates released via the Regulatory News Service (RNS), typically falls under the general 'Regulatory Filings' category if a more specific code like 'CAP' (Capital/Financing Update) is not deemed a better fit. Since the core event is a major financing/capital commitment, 'CAP' is highly relevant. However, the document structure and source (RNS) strongly suggest it is a regulatory disclosure. Given the options, 'CAP' describes the *content* (financing), while 'RNS' describes the *delivery mechanism* and acts as a strong fallback for general regulatory news. Since the financing is the primary subject, 'CAP' is the most descriptive filing type for the *event*. I will select 'CAP' as it details a 'Capital/Financing Update'.
2020-04-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.